Within our institution, vancomycin is generally considered the first-line therapy for most infections caused by gram-positive organisms. Despite extensive experience with vancomycin, achieving a ...

Dr. Haldar will describe his work towards designing multi-target acting next-generation analogues which possess additional modes of action and have demonstrated superior efficacy in tackling ...

It exhibits concentration-independent bactericidal activity against gram-positive bacteria ... Doripenem is an injectable carbapenem antibiotic with a spectrum of activity comparable to that ...

Most antibiotics either only target Gram-positive bacteria or they are broad-spectrum ... The only way to delay it is by improving antibiotic stewardship, he noted. The team’s next goal is to study ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...